2型糖尿病与房颤的相关性研究进展
Research Progress on the Relationship between Type 2 Diabetes Mellitus and Atrial Fibrillation
DOI: 10.12677/acm.2025.15102981, PDF,   
作者: 刘柏燕：黑龙江中医药大学研究生院，黑龙江 哈尔滨；崔健昆*：黑龙江中医药大学附属第一医院心血管病四科，黑龙江 哈尔滨
关键词: 2型糖尿病；房颤；相关性分析；Type 2 Diabetes Mellitus； Atrial Fibrillation； Correlation Analysis
摘要: 2型糖尿病(T2DM)是全球心血管并发症的主要危险因素。心房颤动(AF)是最常见的室上性心律失常。两者的发病率都呈逐年上升。大型研究和荟萃分析表明AF和T2DM之间存在明显联系，从而确定了T2DM患者发生AF的风险。基于这两种疾病与心血管疾病发病率和死亡率的高风险之间的联系。在本篇综述中，我们结合这两种实体的病理生理机制，以及现有可用于AF糖尿病患者的治疗方案，为其提供最新依据。
Abstract: Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular complications worldwide. Atrial fibrillation (AF) is the most common supraventricular arrhythmia. The incidence rate of both has increased year by year. Large scale studies and meta-analyses have shown a clear association between AF and T2DM, thus determining the risk of AF in T2DM patients. Based on the association between these two diseases and the high risk of cardiovascular disease incidence rate and mortality. In this review, we combine the pathophysiological mechanisms of these two entities, as well as the existing treatment schemes for AF diabetes patients, to provide the latest basis for them.
文章引用：刘柏燕, 崔健昆. 2型糖尿病与房颤的相关性研究进展[J]. 临床医学进展, 2025, 15(10): 2046-2052. https://doi.org/10.12677/acm.2025.15102981

参考文献

[1] Huxley, R.R., Filion, K.B., Konety, S. and Alonso, A. (2011) Meta-Analysis of Cohort and Case-Control Studies of Type 2 Diabetes Mellitus and Risk of Atrial Fibrillation. The American Journal of Cardiology, 108, 56-62. [Google Scholar] [CrossRef] [PubMed]
[2] Qi, W., Zhang, N., Korantzopoulos, P., Letsas, K.P., Cheng, M., Di, F., et al. (2017) Serum Glycated Hemoglobin Level as a Predictor of Atrial Fibrillation: A Systematic Review with Meta-Analysis and Meta-Regression. PLOS ONE, 12, e0170955. [Google Scholar] [CrossRef] [PubMed]
[3] Gumprecht, J., Lip, G.Y.H., Sokal, A., Średniawa, B., Mitręga, K., Stokwiszewski, J., et al. (2021) Relationship between Diabetes Mellitus and Atrial Fibrillation Prevalence in the Polish Population: A Report from the Non-Invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) Prospective Cross-Sectional Observational Study. Cardiovascular Diabetology, 20, Article No. 128. [Google Scholar] [CrossRef] [PubMed]
[4] Xu, J., Sun, Y., Gong, D. and Fan, Y. (2022) Impact of Preexisting Diabetes Mellitus on Cardiovascular and All-Cause Mortality in Patients with Atrial Fibrillation: A Meta-Analysis. Frontiers in Endocrinology, 13, Article 921159. [Google Scholar] [CrossRef] [PubMed]
[5] Du, X., Ninomiya, T., de Galan, B., Abadir, E., Chalmers, J., Pillai, A., et al. (2009) Risks of Cardiovascular Events and Effects of Routine Blood Pressure Lowering among Patients with Type 2 Diabetes and Atrial Fibrillation: Results of the ADVANCE Study. European Heart Journal, 30, 1128-1135. [Google Scholar] [CrossRef] [PubMed]
[6] Russo, I. and Frangogiannis, N.G. (2016) Diabetes-Associated Cardiac Fibrosis: Cellular Effectors, Molecular Mechanisms and Therapeutic Opportunities. Journal of Molecular and Cellular Cardiology, 90, 84-93. [Google Scholar] [CrossRef] [PubMed]
[7] Ziolo, M.T. and Mohler, P.J. (2015) Defining the Role of Oxidative Stress in Atrial Fibrillation and Diabetes. Journal of Cardiovascular Electrophysiology, 26, 223-225. [Google Scholar] [CrossRef] [PubMed]
[8] Guo, Y., Lip, G.Y.H. and Apostolakis, S. (2012) Inflammation in Atrial Fibrillation. Journal of the American College of Cardiology, 60, 2263-2270. [Google Scholar] [CrossRef] [PubMed]
[9] Liu, C., Fu, H., Li, J., Yang, W., Cheng, L., Liu, T., et al. (2012) Hyperglycemia Aggravates Atrial Interstitial Fibrosis, Ionic Remodeling and Vulnerability to Atrial Fibrillation in Diabetic Rabbits. The Anatolian Journal of Cardiology, 12, 543-550. [Google Scholar] [CrossRef] [PubMed]
[10] Kato, T., Yamashita, T., Sekiguchi, A., Tsuneda, T., Sagara, K., Takamura, M., et al. (2008) Ages-Rage System Mediates Atrial Structural Remodeling in the Diabetic Rat. Journal of Cardiovascular Electrophysiology, 19, 415-420. [Google Scholar] [CrossRef] [PubMed]
[11] Tiwari, S., Schirmer, H., Jacobsen, B.K., Hopstock, L.A., Nyrnes, A., Heggelund, G., et al. (2015) Association between Diastolic Dysfunction and Future Atrial Fibrillation in the Tromsø Study from 1994 to 2010. Heart, 101, 1302-1308. [Google Scholar] [CrossRef] [PubMed]
[12] Chao, T., Suenari, K., Chang, S., Lin, Y., Lo, L., Hu, Y., et al. (2010) Atrial Substrate Properties and Outcome of Catheter Ablation in Patients with Paroxysmal Atrial Fibrillation Associated with Diabetes Mellitus or Impaired Fasting Glucose. The American Journal of Cardiology, 106, 1615-1620. [Google Scholar] [CrossRef] [PubMed]
[13] Watanabe, M., Yokoshiki, H., Mitsuyama, H., Mizukami, K., Ono, T. and Tsutsui, H. (2012) Conduction and Refractory Disorders in the Diabetic Atrium. American Journal of Physiology-Heart and Circulatory Physiology, 303, H86-H95. [Google Scholar] [CrossRef] [PubMed]
[14] Demir, K., Avci, A., Kaya, Z., Marakoglu, K., Ceylan, E., Yilmaz, A., et al. (2016) Assessment of Atrial Electromechanical Delay and P-Wave Dispersion in Patients with Type 2 Diabetes Mellitus. Journal of Cardiology, 67, 378-383. [Google Scholar] [CrossRef] [PubMed]
[15] Kuehl, M. and Stevens, M.J. (2012) Cardiovascular Autonomic Neuropathies as Complications of Diabetes Mellitus. Nature Reviews Endocrinology, 8, 405-416. [Google Scholar] [CrossRef] [PubMed]
[16] Rizzo, M.R., Sasso, F.C., Marfella, R., Siniscalchi, M., Paolisso, P., Carbonara, O., et al. (2015) Autonomic Dysfunction Is Associated with Brief Episodes of Atrial Fibrillation in Type 2 Diabetes. Journal of Diabetes and Its Complications, 29, 88-92. [Google Scholar] [CrossRef] [PubMed]
[17] Ko, S.H., Park, Y.M., Yun, J.S., et al. (2018) Severe Hypoglycemia Is a Risk Factor for Atrial Fibrillation in Type 2 Diabetes Mellitus: Nationwide Population-Based Cohort Study. Journal of Diabetes and its Complications, 32, 157-163. [Google Scholar] [CrossRef] [PubMed]
[18] Fatemi, O., Yuriditsky, E., Tsioufis, C., Tsachris, D., Morgan, T., Basile, J., et al. (2014) Impact of Intensive Glycemic Control on the Incidence of Atrial Fibrillation and Associated Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). The American Journal of Cardiology, 114, 1217-1222. [Google Scholar] [CrossRef] [PubMed]
[19] Fiaschi, T., Magherini, F., Gamberi, T., Lucchese, G., Faggian, G., Modesti, A., et al. (2014) Hyperglycemia and Angiotensin II Cooperate to Enhance Collagen I Deposition by Cardiac Fibroblasts through a ROS-STAT3-Dependent Mechanism. Biochimica et Biophysica Acta—Molecular Cell Research, 1843, 2603-2610. [Google Scholar] [CrossRef] [PubMed]
[20] Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J., et al. (2006) Activation of Oxidative Stress by Acute Glucose Fluctuations Compared with Sustained Chronic Hyperglycemia in Patients with Type 2 Diabetes. Journal of the American Medical Association, 295, 1681-1687. [Google Scholar] [CrossRef] [PubMed]
[21] Staszewsky, L., Cortesi, L., Baviera, M., Tettamanti, M., Marzona, I., Nobili, A., et al. (2015) Diabetes Mellitus as Risk Factor for Atrial Fibrillation Hospitalization: Incidence and Outcomes over Nine Years in a Region of Northern Italy. Diabetes Research and Clinical Practice, 109, 476-484. [Google Scholar] [CrossRef] [PubMed]
[22] Pallisgaard, J.L., Schjerning, A., Lindhardt, T.B., Procida, K., Hansen, M.L., Torp-Pedersen, C., et al. (2016) Risk of Atrial Fibrillation in Diabetes Mellitus: A Nationwide Cohort Study. European Journal of Preventive Cardiology, 23, 621-627. [Google Scholar] [CrossRef] [PubMed]
[23] Bhupathiraju, S.N. and Hu, F.B. (2016) Epidemiology of Obesity and Diabetes and Their Cardiovascular Complications. Circulation Research, 118, 1723-1735. [Google Scholar] [CrossRef] [PubMed]
[24] Tedrow, U.B., Conen, D., Ridker, P.M., Cook, N.R., Koplan, B.A., Manson, J.E., et al. (2010) The Long and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation. Journal of the American College of Cardiology, 55, 2319-2327. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, T.J. (2004) Obesity and the Risk of New-Onset Atrial Fibrillation. Journal of the American Medical Association, 292, 2471-2477. [Google Scholar] [CrossRef] [PubMed]
[26] Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. (2013) Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 369, 1317-1326. [Google Scholar] [CrossRef] [PubMed]
[27] Saisho, Y. (2015) Metformin and Inflammation: Its Potential beyond Glucose-Lowering Effect. Endocrine, Metabolic & Immune Disorders-Drug Targets, 15, 196-205. [Google Scholar] [CrossRef] [PubMed]
[28] Wang, J., Zhu, L., Hu, K., Tang, Y., Zeng, X., Liu, J., et al. (2017) Effects of Metformin Treatment on Serum Levels of C-Reactive Protein and Interleukin-6 in Women with Polycystic Ovary Syndrome. Medicine, 96, e8183. [Google Scholar] [CrossRef] [PubMed]
[29] Kume, O., Takahashi, N., Wakisaka, O., Nagano-Torigoe, Y., Teshima, Y., Nakagawa, M., et al. (2011) Pioglitazone Attenuates Inflammatory Atrial Fibrosis and Vulnerability to Atrial Fibrillation Induced by Pressure Overload in Rats. Heart Rhythm, 8, 278-285. [Google Scholar] [CrossRef] [PubMed]
[30] Buckingham, R.E. (2005) Thiazolidinediones: Pleiotropic Drugs with Potent Anti-Inflammatory Properties for Tissue Protection. Hepatology Research, 33, 167-170. [Google Scholar] [CrossRef] [PubMed]
[31] Theofilis, P., Sagris, M., Oikonomou, E., Antonopoulos, A.S., Siasos, G., Tsioufis, K., et al. (2022) Pleiotropic Effects of SGLT2 Inhibitors and Heart Failure Outcomes. Diabetes Research and Clinical Practice, 188, Article 109927. [Google Scholar] [CrossRef] [PubMed]
[32] Theofilis, P., Antonopoulos, A.S., Katsimichas, T., Oikonomou, E., Siasos, G., Aggeli, C., et al. (2022) The Impact of SGLT2 Inhibition on Imaging Markers of Cardiac Function: A Systematic Review and Meta-Analysis. Pharmacological Research, 180, Article 106243. [Google Scholar] [CrossRef] [PubMed]
[33] Theofilis, P., Vordoni, A. and Kalaitzidis, R.G. (2022) Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin. Life, 12, Article 1663. [Google Scholar] [CrossRef] [PubMed]
[34] Theofilis, P., Sagris, M., Oikonomou, E., Antonopoulos, A.S., Siasos, G., Tsioufis, K., et al. (2022) The Anti-Inflammatory Effect of Novel Antidiabetic Agents. Life, 12, Article 1829. [Google Scholar] [CrossRef] [PubMed]
[35] Hankey, G.J., Jamrozik, K., Broadhurst, R.J., Forbes, S. and Anderson, C.S. (2002) Long-Term Disability after First-Ever Stroke and Related Prognostic Factors in the Perth Community Stroke Study, 1989-1990. Stroke, 33, 1034-1040. [Google Scholar] [CrossRef] [PubMed]
[36] Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., et al. (2016) 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS. European Heart Journal, 37, 2893-2962. [Google Scholar] [CrossRef] [PubMed]
[37] Patti, G., Lucerna, M., Cavallari, I., Ricottini, E., Renda, G., Pecen, L., et al. (2017) Insulin-Requiring versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients with Atrial Fibrillation. Journal of the American College of Cardiology, 69, 409-419. [Google Scholar] [CrossRef] [PubMed]
[38] Patti, G., Cavallari, I., Andreotti, F., Calabrò, P., Cirillo, P., Denas, G., et al. (2019) Prevention of Atherothrombotic Events in Patients with Diabetes Mellitus: From Antithrombotic Therapies to New-Generation Glucose-Lowering Drugs. Nature Reviews Cardiology, 16, 113-130. [Google Scholar] [CrossRef] [PubMed]
[39] Cheung, C., Sing, C., Lau, W.C.Y., Li, G.H.Y., Lip, G.Y.H., Tan, K.C.B., et al. (2021) Treatment with Direct Oral Anticoagulants or Warfarin and the Risk for Incident Diabetes among Patients with Atrial Fibrillation: A Population-Based Cohort Study. Cardiovascular Diabetology, 20, Article No. 71. [Google Scholar] [CrossRef] [PubMed]
[40] Ebert, M., Stegmann, C., Kosiuk, J., Dinov, B., Richter, S., Arya, A., et al. (2017) Predictors, Management, and Outcome of Cardioversion Failure Early after Atrial Fibrillation Ablation. EP Europace, 20, 1428-1434. [Google Scholar] [CrossRef] [PubMed]
[41] Abadie, B.Q., Hansen, B., Walker, J., Deyo, Z., Biese, K., Armbruster, T., et al. (2019) Likelihood of Spontaneous Cardioversion of Atrial Fibrillation Using a Conservative Management Strategy among Patients Presenting to the Emergency Department. The American Journal of Cardiology, 124, 1534-1539. [Google Scholar] [CrossRef] [PubMed]
[42] Handelsman, Y., Bunch, T.J., Rodbard, H.W., Steinberg, B.A., Thind, M., Bigot, G., et al. (2022) Impact of Dronedarone on Patients with Atrial Fibrillation and Diabetes: A Sub-Analysis of the ATHENA and EURIDIS/ADONIS Studies. Journal of Diabetes and its Complications, 36, Article 108227. [Google Scholar] [CrossRef] [PubMed]
[43] Iervasi, G., Clerico, A., Bonini, R., Nannipieri, M., et al. (1998) Effect of Antiarrhythmic Therapy with Intravenous Loading Dose of Amiodarone: Evidence for an Altered Response in Diabetic Patients. International Journal of Clinical Pharmacy, 18, 109-120.
[44] Veglio, M., Bruno, G., Borra, M., Macchia, G., Bargero, G., D’errico, N., et al. (2002) Prevalence of Increased QT Interval Duration and Dispersion in Type 2 Diabetic Patients and Its Relationship with Coronary Heart Disease: A Population-Based Cohort. Journal of Internal Medicine, 251, 317-324. [Google Scholar] [CrossRef] [PubMed]
[45] D'Angelo, R.N., Rahman, M., Khanna, R., Yeh, R.W., Goldstein, L., Yadalam, S., et al. (2021) Limited Duration of Antiarrhythmic Drug Use for Newly Diagnosed Atrial Fibrillation in a Nationwide Population under Age 65. Journal of Cardiovascular Electrophysiology, 32, 1529-1537. [Google Scholar] [CrossRef] [PubMed]
[46] Kirchhof, P., Camm, A.J., Goette, A., Brandes, A., Eckardt, L., Elvan, A., et al. (2020) Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. New England Journal of Medicine, 383, 1305-1316. [Google Scholar] [CrossRef] [PubMed]
[47] Kim, M.H., Yu, H.T., Park, Y.J., et al. (2022) Diabetes Mellitus Is an Independent Risk Factor for a Stiff Left Atrial Physiology after Catheter Ablation for Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 9, Article 828478. [Google Scholar] [CrossRef] [PubMed]
[48] Wang, A., Truong, T., Black-Maier, E., Green, C., Campbell, K.B., Barnett, A.S., et al. (2020) Catheter Ablation of Atrial Fibrillation in Patients with Diabetes Mellitus. Heart Rhythm O2, 1, 180-188. [Google Scholar] [CrossRef] [PubMed]
[49] Anselmino, M., Matta, M., D’ascenzo, F., Pappone, C., Santinelli, V., Bunch, T.J., et al. (2015) Catheter Ablation of Atrial Fibrillation in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Europace, 17, 1518-1525. [Google Scholar] [CrossRef] [PubMed]

为你推荐